NASDAQ
ACRV

Acrivon Therapeutics Inc. Common Stock

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Acrivon Therapeutics Inc. Common Stock Stock Price

Vitals

Today's Low:
$11
Today's High:
$11.49
Open Price:
$11.49
52W Low:
$10.9006
52W High:
$25.47
Prev. Close:
$11.59
Volume:
15575

Company Statistics

Market Cap.:
$458.42 million
Book Value:
-25.418
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
0%
Return on Equity TTM:
0%

Company Profile

Acrivon Therapeutics Inc. Common Stock had its IPO on 2022-11-15 under the ticker symbol ACRV.

The company operates in the Healthcare sector and Biotechnology industry. Acrivon Therapeutics Inc. Common Stock has a staff strength of 39 employees.

Stock update

Shares of Acrivon Therapeutics Inc. Common Stock opened at $11.49 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $11 - $11.49, and closed at $11.03.

This is a -4.83% slip from the previous day's closing price.

A total volume of 15,575 shares were traded at the close of the day’s session.

In the last one week, shares of Acrivon Therapeutics Inc. Common Stock have slipped by -5.81%.

Acrivon Therapeutics Inc. Common Stock's Key Ratios

Acrivon Therapeutics Inc. Common Stock has a market cap of $458.42 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months Acrivon Therapeutics Inc. Common Stock’s revenue was $0 with a gross profit of $0 and an EBITDA of $-26730000. The EBITDA ratio measures Acrivon Therapeutics Inc. Common Stock's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Acrivon Therapeutics Inc. Common Stock’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.

In Q3, Acrivon Therapeutics Inc. Common Stock’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Acrivon Therapeutics Inc. Common Stock’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.43 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Acrivon Therapeutics Inc. Common Stock’s profitability.

Acrivon Therapeutics Inc. Common Stock stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -9.3912. Its price to sales ratio in the trailing 12-months stood at 0.

Acrivon Therapeutics Inc. Common Stock stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$87.71 million
Total Liabilities
$6.39 million
Operating Cash Flow
$0
Capital Expenditure
$426000
Dividend Payout Ratio
0%

Acrivon Therapeutics Inc. Common Stock ended 2024 with $87.71 million in total assets and $0 in total liabilities. Its intangible assets were valued at $87.71 million while shareholder equity stood at $-45616000.00.

Acrivon Therapeutics Inc. Common Stock ended 2024 with $0 in deferred long-term liabilities, $6.39 million in other current liabilities, 2000.00 in common stock, $-47103000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $32.08 million and cash and short-term investments were $76.82 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Acrivon Therapeutics Inc. Common Stock’s total current assets stands at $78.67 million while long-term investments were $0 and short-term investments were $44.74 million. Its net receivables were $0 compared to accounts payable of $5.67 million and inventory worth $0.

In 2024, Acrivon Therapeutics Inc. Common Stock's operating cash flow was $0 while its capital expenditure stood at $426000.

Comparatively, Acrivon Therapeutics Inc. Common Stock paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$11.03
52-Week High
$25.47
52-Week Low
$10.9006
Analyst Target Price
$21

Acrivon Therapeutics Inc. Common Stock stock is currently trading at $11.03 per share. It touched a 52-week high of $25.47 and a 52-week low of $25.47. Analysts tracking the stock have a 12-month average target price of $21.

Its 50-day moving average was $11.99 and 200-day moving average was $13.54 The short ratio stood at 2.6 indicating a short percent outstanding of 0%.

Around 3179.9% of the company’s stock are held by insiders while 7170.8% are held by institutions.

Frequently Asked Questions About Acrivon Therapeutics Inc. Common Stock

The stock symbol (also called stock or share ticker) of Acrivon Therapeutics Inc. Common Stock is ACRV

The IPO of Acrivon Therapeutics Inc. Common Stock took place on 2022-11-15

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$12.18
0.07
+0.58%
$1.07
-0.09
-7.76%
$286.53
1.71
+0.6%
$79.38
-0.8
-1%
$24.65
0.21
+0.86%
$2.72
0.01
+0.37%
Forza X1 Inc (FRZA)
$0.87
-0.02
-2.01%
$1.5
-0.2
-11.76%
$1.4
0.05
+3.7%
$0.8
0.01
+1.14%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3). The AP3 platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients predicted to benefit from its drug candidates. The company’s lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, is being advanced in a potentially registrational Phase 2 trial across various tumor types. It is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1 and PKMYT1. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Address

480 Arsenal Way, Watertown, MA, United States, 02472